This post was originally published on this site.
A promisingdrug combinationcould help people with leukemia who don’t respond to traditional treatments, according to new research.
A team at Oregon Health and Science University made the discovery by analyzing samples from more than 300 patients withacute myeloid leukemia, or AML.
More than 20,000 Americans are diagnosed with AML each year, making it one of the most common types of leukemia, data show.It is also one of the most aggressive.
WHY ‘STARVING CANCER’ COULD BE KEY TO SLOWING DISEASE GROWTH, ACCORDING TO DOCTORS
The researchers paired venetoclax, a drug commonly used to treat leukemia, with palbociclib, which is used forbreast cancer.This resulted in significantly stronger and more durable leukemia-fighting activity than venetoclax alone.
The findings were confirmed in human tissue samples and in mouse models carrying human leukemia cells.
Venetoclax, a drug commonly used to treat leukemia, paired with palbociclib, a cell-cycle inhibitor used in breast cancer treatment, resulted in stronger leukemia-fighting activity than venetoclax alone.(iStock)
“The data show that this drug regimen may be especially effective in patients whose tumors exhibit features that cause resistance to the current standard of care,frontline therapies,” Jeffrey Tyner, professor of cell, developmental and cancer biology in the Oregon Health &Science University�
NEW CANCER THERAPY HUNTS AND DESTROYS DEADLY TUMORS IN MAJOR BREAKTHROUGH STUDY
Tyner, who is part of the research team, noted that initial testing explored a broad range of drug combinations and did not begin with any specific “favorites.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Among all the pairings tested, including current standard-of-care regimens, the leukemia and breast cancer drug combination showed the most promising results.
“That really motivated us todig deeperinto why it works so well — and why it appears to overcome resistance seen with current therapy,” Melissa Stewart, research assistant professor at OHSU and lead author of the study, said in a press release.
More than 20,000 Americans are diagnosed with AML each year, making it one of the most common types of leukemia.(iStock)
The study found that AML cells exposed to only venetoclax were able to adapt by increasing protein production.Adding palbociclib, however, blocked this adaptation and impeded the cancer cells’ ability to survive.
“In this model, venetoclax alone didn’t extend survival at all — just as we’d expect based onthe genetics,” Stewart said.“But with the combination, the majority of mice lived 11 to 12 months.In fact, one mouse was still alive when the study ended.”
“Unfortunately, almost everyone will eventually have drug resistance.”
The study helps explain the biological reasons behind the better outcomes of this new drug combination, according to Tyner, and sets the stage for clinical trials withreal patients.
![[aggregator] downloaded image for imported item #2225](https://newsview.top/wp-content/uploads/2025/11/ap25156676970821-scaled-1-1024x576.jpg "CDC quietly changes vaccine and autism stance after years of controversy")
![[aggregator] downloaded image for imported item #2218](https://newsview.top/wp-content/uploads/2025/11/older-woman-cancer-patient-nutrition-1024x576.jpg "Why ‘starving cancer’ could be key to slowing disease growth, according to doctors")
![[aggregator] downloaded image for imported item #2212](https://newsview.top/wp-content/uploads/2025/11/cholesterol-arteries-1024x576.jpg "Daily pill slashes 'bad' cholesterol levels by 60% in yearlong trial")
![[aggregator] downloaded image for imported item #2206](https://newsview.top/wp-content/uploads/2025/11/woman-taking-saffron-supplement-1024x576.jpg "Fox News Health Newsletter: Common spice could boost happiness and sexual health")